Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.

Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.

Abstract: The present invention relates to novel piperazine derivatives (I); to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.

Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.

Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.

Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.

Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.

Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.

Abstract: The present invention relates to novel piperazine derivatives (I); to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.

Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.

Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.

Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.

Abstract: A compound of formula (I), wherein R=H or Na, or a salt thereof and an enzyme, obtainable from Streptomyces species, having clavulanic acid dehydrogenase activity which is capable of converting (I) into clavulanic acid.

Abstract: An isolated DNA fragment encoding a protein with CAD activity wherein the protein is clavulanic acid dehydrogenase (CAD) from S. clavuligerus, with the proviso that the isolated DNA fragment is not: (a) the 13.1 kb BglII to SphI fragment of S. clavuligerus; (b) the 10.8 kb EcoRI to BamHI fragment of S. clavuligerus; (c) the 8.8 kb BclI to BclII fragment of S. clavuligerus; (d) the 2.5 kb BglII to BglII fragment of S. clavuligerus; (e) the 60 kb BglII to BamHI fragment of S. clavuligerus; or (f) the 18.0 BclI to SphI fragment of S. clavuligerus.

Abstract: A method of identifying compounds which interact, directly or indirectly, with a target molecule of interest, wherein the target molecule of interest is an RNA, comprises screening compounds for interaction with the (L)-enantiomer of the said RNA, and identifying, as hits, the enantiomers of those compounds for which a said interaction is detected.

Abstract: A process for preparing clavulanic acid and other clavam derivatives using an enzyme system from Streptomyces, particularly S. Clavuligerus.

Abstract: Carbacephalosporin compounds of formula (I), ##STR1## salts thereof, processes for their synthesis and uses thereof, wherein: R.sup.1 is hydrogen, methoxy or formamido; R.sup.2 is an acyl group; CO.sub.2 R.sup.3 is a carboxy group or a carboxylate anion, or R.sup.3 is a carboxy protecting group or a pharmaceutically acceptable salt-forming group or in vivo hydrolysable ester group; R.sup.4, R.sup.5, R.sup.6 and R.sup.7 represent hydrogen or a substituent; R.sup.4 and R.sup.7 may be replaced by a chemical bond between the two carbon atoms shown; R.sup.5 and R.sup.6 may be linked together into a cyclic system. The compounds (I) have antibacterial properties.

Abstract: There is disclosed a variegated leaved red flowering Dogwood tree having purplish red blooms with distinct pinkish-red tipped new growth, olive green and yellow summer foliage with colorful fall foliage ranging from pink through red to purple.

Abstract: A white flowering Dogwood having distinct olive green leaves with a yellow white margin and fall foliage of distinct color which is borne on an unusually vigorous tree that is more resistant to anthracnose than other variegated leaf dogwood trees.

Abstract: A distinctive Dogwood cultivar of the Cornus florida genus and species having bracts which present an overall strong red appearance with white portions at the base of the bracts and white apical notches, the plant being vigorous and with distinct purplish red new growth, and resistance to powdery mildew.